智飞生物 (300122)
Chongqing Zhifei Biological Products Co.,Ltd.
K-Line Chart
No K-line data
Stock Details
1. Key Indicators
- Total Shares(W): 239378.97
- Circulating A-Shares(W): 141430.62
- Earnings Per Share(RMB): -0.5040
- Net Assets Per Share(RMB): 12.2531
- Operating Revenue(W RMB): 762740.69
- Total Profit(W RMB): -151328.82
- Net Profit Attributable to Parent(W RMB): -120641.48
- Net Profit Growth Rate(%): -156.10
- Weighted Return on Equity(%): -3.9900
- Operating Cash Flow Per Share(RMB): 1.2470
- Undistributed Profit Per Share(RMB): 10.7919
- Capital Reserve Per Share(RMB): 0.0878
2. Main Business
The main business covers:
- An international, full-industry-chain high-tech biopharmaceutical company integrating R&D, production, sales, distribution, import and export of vaccines and biological products.
3. Company Basic Information
- Company Name: Chongqing Zhifei Biological Products Co., Ltd.
- Listing Date: 2010-09-28
- Industry: Pharmaceutical Manufacturing
- Address: 50th Floor, No. 1 Yunlu Road, Jiangbei District, Chongqing
- Website: www.zhifeishengwu.com
- Company Profile: The Company was established through the overall transformation of the former Chongqing Zhifei Biological Products Co., Ltd. On August 15, 2009, the shareholders' meeting of the limited company agreed to legally transform Chongqing Zhifei Biological Products Co., Ltd. into Chongqing Zhifei Biological Products Co., Ltd. This change was based on the audit benchmark date of June 30, 2009. The net assets of the limited company confirmed by Zhongrui Yuehua Certified Public Accountants' Audit Report No. 2172 [2009] were RMB 374,761,827.09, which was converted into 360 million shares at a ratio of 1:0.9606. The balance of RMB 14,761,827.09 was transferred to capital reserve. All assets, liabilities and equity of the original limited company were inherited by the joint stock company. On September 7, 2009, the company registered with the Chongqing Administration for Industry and Commerce and obtained the "Business License" with registration number 500105000065802. The registered capital and paid-in capital were both RMB 360 million, and the legal representative was Jiang Rensheng.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Hong Kong Securities Clearing Company Ltd. | Northbound Capital | 3356.08 | 2.37 |
| 2 | E Fund ChiNext ETF | Fund | 2415.90 | 1.71 |
| 3 | Huatai-PineBridge CSI 300 ETF | Fund | 2042.08 | 1.44 |
| 4 | Shanghai Yingshui Investment Management Co., Ltd. - Yingshui Heli No.13 Private Securities Investment Fund | Private Securities Investment Fund | 1757.55 | 1.24 |
| 5 | China Merchants Guozheng Bio-medicine Index Securities Investment Fund (LOF) Class A | Fund | 1615.47 | 1.14 |
| 6 | E Fund CSI 300 Healthcare ETF | Fund | 1499.56 | 1.06 |
| 7 | Tianhong Guozheng Bio-medicine ETF | Fund | 567.27 | 0.40 |
| 8 | Guotai CSI Bio-medicine ETF | Fund | 382.47 | 0.27 |
| 9 | E Fund CSI Wind Biotech Index Securities Investment Fund (LOF) Class A | Fund | 128.61 | 0.09 |
| 10 | China Universal Guozheng Bio-medicine ETF | Fund | 103.76 | 0.07 |
5. Concept Sectors
- Biological Vaccine
- Hepatitis Concept
- Innovative Drug
- Weight Loss Drug
- Synthetic Biology
- Margin Trading & Securities Lending
- MSCI Constituent
- Non-Cyclical Stock
- Commitment Not to Reduce Holdings
- High Accounts Receivable
- Heavily Held by Private Funds
- CSI 100
- CSI SME 100
- ChiNext Index
- SZSE 100
- SZSE 300
- CSI 300
- ChiNext 50
- ChiNext 300
- CSI 200
- CSI 300 Non-Cyclical
- ChiNext Blue Chip
- ChiNext Large Cap
- ChiNext Healthcare
- STAR 50 & ChiNext 50
- CSI 300 ESG
- MSCI China A 50
- CSI A 100
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information